Join the 'Hyperkalemia' group to help and get support from people like you.
Posted 5 days ago by Drugs.com
May 18, 2018 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Lokelma (sodium zirconium cyclosilicate), formerly ZS-9, for the treatment of hyperkalemia in adults. Hyperkalemia is a serious condition characterized by high levels of potassium in the blood (greater than 5.0 mEq/L). The risk of hyperkalemia increases significantly for patients with chronic ...
FDA Medwatch Alert: Kayexalate (sodium polystyrene sulfonate): Drug Safety Communication - FDA Recommends Separating Dosing
Posted 6 Sep 2017 by Drugs.com
ISSUE: FDA is recommending that patients avoid taking the potassium-lowering drug sodium polystyrene sulfonate (Kayexalate) at the same time as other medicines taken by mouth. A study found that sodium polystyrene sulfonate binds to many commonly prescribed oral medicines, decreasing the absorption and therefore effectiveness of those oral medicines. To reduce this likelihood, we recommend ...
FDA Approves Supplemental New Drug Application for Veltassa Removing Boxed Warning Regarding Drug-Drug Interactions
Posted 30 Nov 2016 by Drugs.com
REDWOOD CITY, Calif., November 27, 2016 – Relypsa, Inc., a Vifor Pharma company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) with important updates to the label of Veltassa (patiromer) for oral suspension. Veltassa’s label no longer includes a Boxed Warning regarding the separation of Veltassa and other oral medications. ...
Posted 28 Oct 2015 by Drugs.com
October 21, 2015 – The U.S. Food and Drug Administration today approved Veltassa (patiromer for oral suspension) to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high. “Too much potassium in the blood can lead to dangerous, even fatal, changes in heart rhythm,” said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Ren ...
FDA Medwatch Alert: Kayexalate (sodium polystyrene sulfonate): Drug Safety Communication - FDA Requires Drug Interaction Studies
Posted 22 Oct 2015 by Drugs.com
ISSUE: FDA is requiring the Kayexalate manufacturer to conduct studies to investigate Kayexalate’s potential to bind to other medications administered by mouth – drug interactions that could affect how well the other medications work. The approved labeling for Kayexalate describes its potential to decrease absorption of lithium and thyroxine; however, extensive drug-drug interaction studies with K ...
Posted 14 Jul 2015 by Drugs.com
TUESDAY, July 14, 2015 – A new drug decreases dangerously high levels of potassium in people with diabetes-related kidney disease, a new study finds. Potassium is necessary for the heart, kidneys and other organs to work normally, but damage to the kidneys can cause potassium levels to increase to dangerous levels. This condition is called hyperkalemia. Elevated potassium levels are associated ...
Related Drug Support Groups
Novolin R, sodium bicarbonate, Humulin R, insulin regular, sodium polystyrene sulfonate, Kayexalate, Kionex, Novolin R PenFill, Kalexate, view more... calcium gluconate, calcium chloride, Veltassa, Novolin R Innolet, Cal-G, ReliOn / Novolin R, Kalcinate, Cal-GLU, Iletin II Regular Pork, Bell / ans, Iletin Regular, Velosulin BR, Neut, sodium zirconium cyclosilicate, patiromer, Lokelma